SAN FRANCISCO (GenomeWeb) – The Mount Sinai Health system this week spun out a new company, Sema4, that will offer the same genetic tests that had been available to patients at Mt. Sinai, but will now do so nationally.

It also plans to expand the testing menu and will look to integrate machine learning and data science to move into predictive medicine, said Eric Schadt, who will serve as CEO of Sema4. Schadt will also maintain a faculty position at Mt. Sinai, as well as an active lab that will collaborate with Sema4 on building predictive models of disease.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.